These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34387901)

  • 1. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease.
    Ward JL; Chou YY; Yuan L; Dorman KS; Mochel JP
    J Vet Intern Med; 2021 Sep; 35(5):2102-2111. PubMed ID: 34387901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers.
    O'Grady MR; O'Sullivan ML; Minors SL; Horne R
    J Vet Intern Med; 2009; 23(5):977-83. PubMed ID: 19572914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK; Atkins CE; Eriksson A; Hess AM
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
    de Madron E; King JN; Strehlau G; White RV
    Can Vet J; 2011 Nov; 52(11):1219-25. PubMed ID: 22547843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD; Rockwell JE; Fallaw TK; Calvert CA
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival of non-elderly patients with severe heart failure treated with angiotensin-converting enzyme inhibitors assessment of treatment with captopril and enalapril survival study (ACESS).
    Huang CM; Young MS
    Circ J; 2002 Oct; 66(10):886-90. PubMed ID: 12381079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
    Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
    Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
    J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.
    Kvart C; Häggström J; Pedersen HD; Hansson K; Eriksson A; Järvinen AK; Tidholm A; Bsenko K; Ahlgren E; Ilves M; Ablad B; Falk T; Bjerkfås E; Gundler S; Lord P; Wegeland G; Adolfsson E; Corfitzen J
    J Vet Intern Med; 2002; 16(1):80-8. PubMed ID: 11822810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.
    Pouchelon JL; Jamet N; Gouni V; Tissier R; Serres F; Carlos Sampedrano C; Castaignet M; Lefebvre HP; Chetboul V
    J Vet Intern Med; 2008; 22(4):905-14. PubMed ID: 18482278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
    King JN; Hirakawa A; Sonobe J; Otaki H; Sakakibara N; Seewald W; Forster S
    J Vet Sci; 2018 Jan; 19(1):117-128. PubMed ID: 28693297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
    Coffman M; Guillot E; Blondel T; Garelli-Paar C; Feng S; Heartsill S; Atkins CE
    J Vet Intern Med; 2021 Jul; 35(4):1673-1687. PubMed ID: 34028078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR; Minors SL; O'Sullivan ML; Horne R
    J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study.
    Nelveg-Kristensen KE; Busk Madsen M; Torp-Pedersen C; Køber L; Egfjord M; Berg Rasmussen H; Riis Hansen P
    PLoS One; 2015; 10(12):e0144195. PubMed ID: 26633885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta-analysis.
    Donati P; Tarducci A; Zanatta R; Verdier N; Belerenian G; Cordero I; Villalta C; Franco J; Tarragona L
    J Small Anim Pract; 2022 May; 63(5):362-371. PubMed ID: 34905219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.
    Atkins CE; Keene BW; Brown WA; Coats JR; Crawford MA; DeFrancesco TC; Edwards NJ; Fox PR; Lehmkuhl LB; Luethy MW; Meurs KM; Petrie JP; Pipers FS; Rosenthal SL; Sidley JA; Straus JH
    J Am Vet Med Assoc; 2007 Oct; 231(7):1061-9. PubMed ID: 17916031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.